CATX

Perspective Therapeutics, Inc.
$1.21
-0.40 (-24.84%)
Mkt Cap 138.12M
Volume 9,614,058
52W Range 1.115-6.16
Sector Healthcare
Beta 1.85
EPS (TTM) -1.56 USD
P/E Ratio -1.96
Revenue (TTM) 366,000 USD
Rev Growth (5Y) -35.3%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
11.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 0 1.45M 1.43M 7.10M 10.79M 10.05M 9.68M 7.31M 5.92M 4.76M 4.77M 4.61M
Net Income (103.12M) (79.28M) (46.51M) (14.67M) (7.27M) (3.19M) (3.27M) (4.85M) (6.70M) (6.16M) (4.71M) (3.68M)
EPS -1.40 -1.23 -0.85 -0.27 -0.50 -0.06 -0.05 -0.07 -0.12 -0.11 -0.09 -0.07
Free Cash Flow (95.23M) (72.71M) (37.98M) (10.68M) (7.98M) (3.22M) (3.91M) (5.49M) (6.05M) (6.26M) (4.36M) (3.65M)
FCF / Share -1.29 -1.13 -0.69 -0.19 -0.56 -0.06 -0.06 -0.08 -0.11 -0.11 -0.08 -0.07
Operating CF (82.48M) (18.29M) (36.91M) (10.40M) (7.71M) (2.84M) (3.64M) (5.05M) (5.71M) (5.71M) (3.88M) (3.52M)
Total Assets 266.97M 341.10M 97.89M 58.09M 64.44M 15.51M 8.70M 9.42M 7.46M 12.27M 18.10M 23.00M
Total Debt 3.25M 4.06M 2.55M 524,000 524,000 897,000 1.00M 0 0 0 0 0
Cash & Equiv 30.63M 61.58M 9.24M 20.99M 55.89M 9.59M 2.39M 5.33M 2.60M 5.93M 10.14M 5.23M
Book Value 207.03M 290.67M 75.18M 54.64M 61.28M 12.77M 5.72M 7.68M 5.03M 10.60M 16.40M 20.78M
Return on Equity -0.50 -0.27 -0.62 -0.27 -0.12 -0.25 -0.57 -0.63 -1.33 -0.58 -0.29 -0.18
CATX News
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Oct 23, 2026 01:02 PM · marketbeat.com
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
Oct 23, 2026 06:49 AM · globenewswire.com
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Oct 08, 2026 02:16 AM · globenewswire.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research
Oct 07, 2026 04:07 AM · defenseworld.net
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
Oct 07, 2026 02:16 AM · globenewswire.com
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts
Oct 06, 2026 10:45 PM · defenseworld.net
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
Oct 02, 2026 07:46 AM · globenewswire.com
This $3 Biotech Could Be Worth $11.45, Analyst Says
Sep 18, 2026 09:52 AM · benzinga.com
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Sep 14, 2026 02:16 AM · globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Sep 11, 2026 02:00 AM · globenewswire.com